A Randomized, Blinded, Placebo-Controlled, Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection
Latest Information Update: 03 Jul 2023
At a glance
- Drugs ABI-H3733 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Assembly Biosciences
- 28 Jun 2023 Status changed from active, no longer recruiting to completed.
- 24 Jun 2023 Preliminary results assessing the safety, pharmacokinetics, and antiviral activity of ABI-H3733 in HBeAg negative patients from completed cohorts, presented at the European Association for the Study of the Liver Congress 2023.
- 21 Jun 2023 Results presented in an Assembly Biosciences media release.